2,002 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Bridgewater Associates LP

Bridgewater Associates LP acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,002 shares of the biopharmaceutical company’s stock, valued at approximately $551,000.

A number of other large investors have also recently bought and sold shares of ALNY. TD Asset Management Inc boosted its holdings in Alnylam Pharmaceuticals by 6.0% in the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after purchasing an additional 27,592 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after buying an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after buying an additional 100,000 shares during the last quarter. Swiss National Bank grew its holdings in Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after acquiring an additional 1,000 shares during the period. Finally, Eagle Asset Management Inc. raised its position in Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after acquiring an additional 63,385 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 8,370 shares of company stock valued at $2,100,703. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $253.01 on Tuesday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The stock has a market cap of $32.63 billion, a PE ratio of -97.31 and a beta of 0.39. The firm has a fifty day moving average price of $271.07 and a 200 day moving average price of $242.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The firm’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.15 earnings per share. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Raymond James lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.